ADC Therapeutics SA
ADCT
$3.54
-$0.41-10.38%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 75.21M | 77.25M | 75.82M | 70.84M | 70.72M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 75.21M | 77.25M | 75.82M | 70.84M | 70.72M |
| Cost of Revenue | 89.46M | 94.81M | 89.40M | 89.85M | 92.92M |
| Gross Profit | -14.26M | -17.57M | -13.58M | -19.01M | -22.20M |
| SG&A Expenses | 79.37M | 81.03M | 83.00M | 85.91M | 90.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 197.76M | 204.77M | 201.32M | 201.49M | 208.91M |
| Operating Income | -122.55M | -127.52M | -125.51M | -130.65M | -138.20M |
| Income Before Tax | -165.84M | -168.76M | -149.67M | -157.68M | -168.49M |
| Income Tax Expenses | 1.10M | 1.19M | 168.00K | 166.00K | 43.66M |
| Earnings from Continuing Operations | -166.94 | -169.94 | -149.84 | -157.85 | -212.15 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -166.94M | -169.94M | -149.84M | -157.85M | -212.15M |
| EBIT | -122.55M | -127.52M | -125.51M | -130.65M | -138.20M |
| EBITDA | -121.50M | -126.14M | -124.16M | -129.32M | -136.87M |
| EPS Basic | -1.45 | -1.57 | -1.45 | -1.66 | -2.40 |
| Normalized Basic EPS | -0.83 | -0.90 | -0.91 | -1.03 | -1.17 |
| EPS Diluted | -1.45 | -1.57 | -1.45 | -1.66 | -2.40 |
| Normalized Diluted EPS | -0.83 | -0.90 | -0.91 | -1.03 | -1.17 |
| Average Basic Shares Outstanding | 462.79M | 431.17M | 413.12M | 388.47M | 365.36M |
| Average Diluted Shares Outstanding | 462.79M | 431.17M | 413.12M | 388.47M | 365.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |